Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020
Viela Bio (Nasdaq: VIE) announced the acceptance of four abstracts for the 8th Joint Congress of ACTRIMS and ECTRIMS, taking place virtually from September 11-13, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Viela Bio (Nasdaq: VIE) announced the acceptance of four abstracts for the 8th Joint Congress of ACTRIMS and ECTRIMS, taking place virtually from September 11-13, 2020. This includes a late-breaker presentation on pharmacodynamic modeling of inebilizumab for neuromyelitis optica spectrum disorders scheduled for September 26, 2020. Presentations will cover critical findings from the N-MOmentum trial, highlighting insights into patient responses and MRI activity in neuromyelitis optica.
Positive
- Four abstracts accepted for prestigious scientific congress highlighting ongoing research.
- Late-breaker presentation may attract attention to inebilizumab's effectiveness.
Negative
- None.
Details
News Market Reaction – VIE
The recorded move for VIE in the trading session of this news was +4.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced that four abstracts have been accepted for presentation, including a late-breaker, at the upcoming 8th Joint Congress of the American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The congress will be held virtually on September 11-13, 2020 with an Encore event featuring late-breaker and COVID-19 presentations on September 26, 2020.
Poster Presentations:
Title: AQP4-IgG seronegative patients in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder (P0189)
Date: Friday, September 11, 2020
Time: 8:00 AM EDT
Title: Serum neurofilament light chain levels (sNfL) correlate with attack-related disability in neuromyelitis optica (P0155)
Date: Friday, September 11, 2020
Time: 8:00 AM EDT
Title: Quiescent MRI activity in NMOSD: results from the N-MOmentum randomized placebo-
controlled trial (P0229)
Date: Friday, September 11, 2020
Time: 8:00 AM EDT
Late-Breaker Presentation:
Title: Pharmacodynamic modeling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders (LB1239)
Date: Saturday, September 26, 2020
Time: 8:00 AM EDT
About Viela Bio
Viela Bio, headquartered in Gaithersburg, Maryland, is a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases. For more information, please visit www.vielabio.com.
Source: Viela Bio
Contacts:
Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com
Media:
Solebury Trout
Amy Bonanno
914-450-0349
abonanno@soleburytrout.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.